Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | GAA | P10253 | 7/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PKLR | P30613 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13271173 | 0.95 | USP2 (0.62) | USP2GAAL3MBTL1MAPTPKM | |
| SCHEMBL8692256 | 0.85 | ALDH1A1 (0.68) | GAAMAPTPOLBHTTLMNA | |
| SCHEMBL15231766 | 0.84 | MAPT (0.65) | USP2GAAL3MBTL1MAPTPKM | |
| SCHEMBL12656054 | 0.83 | KMT2A (0.63) | USP2GAAL3MBTL1MAPTPKM | |
| SCHEMBL5338240 | 0.83 | POLB (0.67) | GAAL3MBTL1PKMPKLRPOLB | |
| Hydrochloric Acid SCHEMBL3246796 | 0.83 | MAPT (0.63) | USP2GAAL3MBTL1MAPTPKM | |
| SCHEMBL16627264 | 0.83 | ATM (0.63) | USP2GAAL3MBTL1PKMPKLR | |
| SCHEMBL8220120 | 0.81 | GAA (0.56) | USP2GAAL3MBTL1MAPTPKM | |
| SCHEMBL13993549 | 0.80 | MEN1 (0.69) | GAAL3MBTL1MAPTPKMPKLR | |
| SCHEMBL3629646 | 0.80 | ALDH1A1 (0.61) | USP2GAAL3MBTL1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117730077-A | 6-substituted naphthalene-1, 3-disulfonic acid derivatives as modulators of extracellular nicotinamide ribophosphate transferase (ENAMPT) for the treatment of, for example, diabetes | 曼彻斯特大学 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023007147-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | THE UNIVERSITY OF MANCHESTER (GB) | 2023-02-02 | — | — | WO | disclosed |
| US-20210380546-A1 | VACCINE ADJUVANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-09 | — | — | US | disclosed |
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | Valo Health, LLC | 2020-06-30 | — | — | US | disclosed |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | VALO HEALTH, INC. | 2015-04-16 | — | — | US | disclosed |
| EP-2820018-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | Genentech, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013127266-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | GENENTECH, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2144890-A1 | METHOD FOR PREPARING HALOGENATED AMINES | Wyeth (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008098103-A1 | METHOD FOR PREPARING HALOGENATED AMINES | WYETH (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288228-B1 | DIAMINOTRIAZINE DERIVATIVES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | disclosed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188659-A1 | Method for Preparing Halogenated Amines | PNMT, ABL1, INMT | USP2 743/4885GAA 2501/4885L3MBTL1 3280/4885 |
| US-10696692-B2 | Amido-benzyl sulfone and sulfoxide derivates | STS, SQOR, SULT1E1 | USP2 3157/4885GAA 1180/4885L3MBTL1 3680/4885 |
| US-20210380546-A1 | VACCINE ADJUVANT | IFNG, TLR9, LY96 | USP2 3978/4885GAA 2120/4885L3MBTL1 3199/4885 |
| US-10196373-B2 | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein | STAT3, STAT1, STAT4 | USP2 638/4885GAA 949/4885L3MBTL1 2601/4885 |
| US-20150104384-A1 | AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES | STS, SULT1E1, CBS | USP2 3457/4885GAA 1131/4885L3MBTL1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.